However, even with near complete inhibition of intratumoural 2-HG production, not all IDH mutant glioma models responded to treatment, but only BT142 displayed significant tumour growth inhibition resulting in a measurable survival benefit. This evidence concerns the gene IDH2 and central nervous system cancer.